Company Analysis

Protara Therapeutics, Inc. (TARA)

Nasdaq: TARA · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2006
Grade5.0
◀ Past 4.0● Present 5.9▶ Future 4.9
6 est.

Filings

326 filings since 2017 beside 319 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026
Due nextNon-accelerated filer and smaller reporting company
10-K Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Mar 31, 2027
10-Q Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by May 15, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 37 days after the quarter ended. The proxy statement was last filed Apr 28, 2026.

Filings a yearinsider forms included
62109504947647169
20192020202120222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 2 times in the last 36 months, the newest Jun 29, 2026.SEC letters: 4 in the last 36 months, the newest May 20, 2026.
Insider forms 319

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 6, 2026 10-Q Quarterly report Sep 30, 2026
Nov 6, 2026 8-K items 2.02, 9.01 Results released · Current report
Aug 13, 2026 SCHEDULE 13G/A Large holder update, amended
Aug 11, 2026 S-8 Employee stock plan registration
Aug 11, 2026 10-Q Quarterly report Jun 30, 2026
Aug 11, 2026 8-K items 2.02, 9.01 Results released · Current report
Jul 7, 2026 SCHEDULE 13G/A Large holder update, amended
Jun 29, 2026 8-K item 5.02 Officer or director change · Current report Jun 26, 2026
Jun 15, 2026 8-K item 5.07 Shareholder vote · Current report Jun 12, 2026
May 28, 2026 424B5 Shelf offering
May 22, 2026 EFFECT Registration effective
May 20, 2026 CORRESP Reply to the SEC
May 19, 2026 UPLOAD SEC comment letter
May 15, 2026 SCHEDULE 13G/A Large holder update, amended
May 14, 2026 S-3 Shelf registration
May 13, 2026 10-Q Quarterly report Mar 31, 2026
May 13, 2026 8-K items 2.02, 9.01 Results released · Current report
Apr 28, 2026 DEFA14A Extra proxy material
Apr 28, 2026 ARS Annual report to shareholders Dec 31, 2025
Apr 28, 2026 DEF 14A Proxy statement Jun 12, 2026
Apr 27, 2026 SCHEDULE 13G Large holder notice
Apr 17, 2026 PRE 14A Preliminary proxy statement
Mar 30, 2026 8-K item 7.01 Investor disclosure (Regulation FD) · Current report
Mar 10, 2026 10-K Annual report Dec 31, 2025
Mar 10, 2026 8-K items 2.02, 9.01 Results released · Current report
Mar 6, 2026 424B7 Resale prospectus supplement
Mar 2, 2026 SCHEDULE 13G Large holder notice
Feb 24, 2026 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report Feb 23, 2026
Feb 17, 2026 SCHEDULE 13G/A Large holder update, amended
Feb 2, 2026 424B7 Resale prospectus supplement
Jan 21, 2026 SCHEDULE 13G/A Large holder update, amended
Dec 15, 2025 8-K items 8.01, 9.01 Other event · Current report
Dec 9, 2025 424B7 Resale prospectus supplement
Dec 8, 2025 8-K items 1.01, 9.01 Major agreement signed · Current report Dec 4, 2025
Dec 5, 2025 424B5 Shelf offering
Dec 4, 2025 424B5 Shelf offering
Dec 3, 2025 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report
Nov 19, 2025 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report
Nov 14, 2025 SCHEDULE 13G/A Large holder update, amended
Nov 10, 2025 10-Q Quarterly report Sep 30, 2025
40 of 326 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton TARA · research, not advice